Navigation Links
Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
Date:5/31/2013

HAYWARD, Calif., May 31, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, announced today that Paul F. Truex , President and Chief Executive Officer, and Dr. Colin Hislop , Senior Vice President and Chief Medical Officer, will present a corporate update at the 2013 Annual Jefferies Global Healthcare Conference.

Anthera will present on at 1:30PM ET, June 6th in Ballroom 1 of the Grand Hyatt Hotel in New York City.

About Blisibimod and PEARL-SC

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens.  However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical studies with BAFF antagonists have reported the potential benefit of BAFF inhibitors in treating patients with lupus and rheumatoid arthritis.

In April 2012, Anthera completed the PEARL-SC Phase 2b clinical study to evaluate the efficacy and safety of subcutaneous blisibimod in patients with active and seropositive lupus. In June and July of 2012 Anthera announced results from PEARL-SC which led to the initiation of a Phase 3 registration plan utilizing the 200mg weekly dose of blisibimod in patients who were afflicted with active lupus despite receiving corticosteroids.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
2. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
3. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
4. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
7. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
8. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
9. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
10. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 ... 2017 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
(Date:8/2/2017)... 2, 2017 CaryRx, a next-generation full-service pharmacy, has ... for patients in the Washington D.C. ... by providing delivery of medications through the convenience of its ... or delivered within one hour to any location in D.C. ... bring this invaluable service to Washington D.C. ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... ... of breastfeeding mothers. These illustrations show the diversity of the breastfeeding mothers, ... a wide range of sizes. These illustrations are also available on tote bags, ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... , ... August 18, 2017 , ... More than 20,000 ... Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions of ... the generous support of the Liberty community. These shoes will save lives from the ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
Breaking Medicine News(10 mins):